Search | Clinical Trials Finder

Conditions: Essential Tremor
Interventions: Sodium Oxybate, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bingham Farms, Michigan

Conditions: Achondroplasia
Interventions: Recifercept; Other
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 10 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: Cocaine-Related Disorders, Substance-Related Disorders
Interventions: Cabergoline, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Torrance, California • Charleston, South Carolina

Conditions: Acne
Interventions: Skin Nutraceutical Supplement, Placebo pill; Dietary Supplement · Other
Lead sponsor: Nutraceutical Wellness Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Vomiting, Nausea, Children, Only
Interventions: Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo; Other · Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newark, Delaware • Kingwood, Texas

Conditions: Parkinson Disease
Interventions: Parkinson's Application, Digital Placebo Application; Device
Lead sponsor: Beats Medical; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more

Conditions: Healthy
Interventions: Probiotic: Bacillus subtilis, Lactobacillus plantarum, Bifidobacterium animalis, Placebo; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 35 Years to 65 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Obesity
Interventions: Hybrid Argon Plasma Coagulation, Endoscopic Sleeve Gastroplasty; Procedure
Lead sponsor: True You Weight Loss; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Inflammatory Bowel Diseases, IBD, Crohn Disease, Ulcerative Colitis
Interventions: SMART-IBD; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more

Conditions: Infertility
Interventions: acupuncture, IVF; Procedure
Lead sponsor: Pacific Fertility Center; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Euvolemic Hyponatremia
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 66
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more

Conditions: Hip Fractures, Muscle Atrophy
Interventions: Blood Flow Restriction with Delfi Tourniquet System Cuff, Routine Post-operative Physical Therapy; Device · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Anorexia, Cachexia, Weight Loss
Interventions: Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 4
States / cities: Anaheim, California • Flat Rock, North Carolina • High Point, North Carolina + 1 more

Conditions: PTSD
Interventions: TNX-102 SL, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more

Conditions: Opioid Use Disorders
Interventions: CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets; Drug
Lead sponsor: Braeburn Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more

Conditions: Down Syndrome, Cognitive Dysfunction
Interventions: Aricept (donepezil hydrochloride), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: San Antonio, Texas • Herndon, Virginia

Conditions: Traumatic Brain Injury, Traumatic Brain Injury (TBI), Hemiplegia and Hemiparesis
Interventions: Transcutaneous Spinal Cord Stimulation, Sham; Procedure · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • West Orange, New Jersey

Search by objective public record fields.

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

A Study to Learn About Recifercept in Patients With Achondroplasia

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

RCT of an Oral Acne Supplement for Adult Women

Inhaled Isopropyl Alcohol for Treatment of Nausea

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Pilot Study to Evaluate the Self-Management of Gait, Speech, and Dexterity Symptoms in Parkinson's Disease Using a Smartphone Application

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Validation Study

SMART-IBD App Trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

In Vitro Fertilization (IVF) and Acupuncture for Infertility

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Long Term Safety of Naldemedine

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Spinal Stimulation and Gait Training to Improve Mobility in TBI